Pfizer Inc. closed $4.65 short of its 52-week high ($31.54), which the company reached on July 30th.
PFE's strong economic moat is threatened by upcoming patent expirations, but its oncology segment shows promising growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback